
```
C:\Documents and Settings\EBernhardt\My Documents\Stnexp\Queries\10764653.str
chain nodes :
```

```
1 2 3 4 5 6 8 9 10 11 12
chain bonds :
   2-7 5-16 7-12 8-15
ring bonds :
   1-2 1-6 2-3 3-4 4-5 5-6 8-9 8-12 9-10 10-11 11-12
exact/norm bonds :
   1-2 1-6 2-3 2-7 3-4 4-5 5-6 8-9 8-12 8-15 9-10
exact bonds :
   5-16 7-12 10-11 11-12
isolated ring systems :
  containing 1 : 8 :
Match level :
   1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:Atom 9:Atom 10:Atom 11:Atom
   12:Atom 15:Atom 16:Atom
Generic attributes :
   16:
   Saturation
                        : Unsaturated
```

7 15 16 ring nodes :

=>

Uploading C:\Documents and Settings\EBernhardt\My Documents\Stnexp\Queries\10764653.str



24 ANSWERS

chain nodes : 7 15 16

ring nodes :

1 2 3 4 5 6 8 9 10 11 12

chain bonds :

2-7 5-16 7-12 8-15

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 8-9 8-12 9-10 10-11 11-12

exact/norm bonds :

8-9 8-12 8-15 9-10 1-2 1-6 2-3 2-7 3-4 4-5 5-6

exact bonds :

5-16 7-12 10-11 11-12 isolated ring systems : containing 1:8:

Match level:

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:Atom 9:Atom 10:Atom

11:Atom 12:Atom 15:Atom 16:Atom

Generic attributes :

16:

Saturation : Unsaturated

L1STRUCTURE UPLOADED

=> s 11

SAMPLE SEARCH INITIATED 17:21:00 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED -226 TO ITERATE

100.0% PROCESSED 226 ITERATIONS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*

BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS:

3619 TO 5421

PROJECTED ANSWERS:

187 TO 773

24 SEA SSS SAM L1

=> d 12 1 5 10

#### 10/764653

L2 ANSWER 1 OF 24 REGISTRY COPYRIGHT 2006 ACS on STN

RN 756753-21-6 REGISTRY

ED Entered STN: 04 Oct 2004

CN Piperazine, 1-(3,5-dimethoxyphenyl)-4-[[3-(1-hydroxyethyl)-1-phenyl-1H-pyrazol-5-yl]carbonyl]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN [4-(3,5-Dimethoxyphenyl)piperazin-1-yl][5-(1-hydroxyethyl)-2-phenyl-2H-pyrazol-3-yl]methanone

MF C24 H28 N4 O4

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER

### \*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 5 OF 24 REGISTRY COPYRIGHT 2006 ACS on STN

RN 756751-46-9 REGISTRY

ED Entered STN: 04 Oct 2004

CN L-Serine, N-[3-[4-[(3-methyl-1-phenyl-1H-pyrazol-5-yl)carbonyl]-1-piperazinyl]benzoyl]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 3-Hydroxy-2-[3-[4-[(5-methyl-2-phenyl-2H-pyrazol-3-yl)carbonyl]piperazin-1-yl]benzoylamino]propanoic acid

FS STEREOSEARCH

MF C25 H27 N5 O5

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER

#### Absolute stereochemistry.

#### \*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 10 OF 24 REGISTRY COPYRIGHT 2006 ACS on STN

729606-48-8 REGISTRY RN

ED Entered STN: 21 Aug 2004

Piperazine, 1-(2,3-dichlorophenyl)-4-[[3-methyl-1-[4-(methylsulfonyl)phenyl]-1H-pyrazol-5-yl]carbonyl]- (9CI) (CA INDEX NAME) OTHER NAMES:

[4-(2,3-Dichlorophenyl)piperazin-1-yl][2-[4-(methanesulfonyl)phenyl]-5-CN methyl-2H-pyrazol-3-yl]methanone

C22 H22 C12 N4 O3 S MF

SR

LCSTN Files: CA, CAPLUS, TOXCENTER, USPATFULL

### \*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

2 REFERENCES IN FILE CA (1907 TO DATE)

2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> s ll sss full

FULL SEARCH INITIATED 17:21:25 FILE 'REGISTRY' FULL SCREEN SEARCH COMPLETED -4560 TO ITERATE

100.0% PROCESSED 4560 ITERATIONS 447 ANSWERS

SEARCH TIME: 00.00.01

L3447 SEA SSS FUL L1

=> save 13

ENTER NAME OR (END):ten764653/a ANSWER SET L3 HAS BEEN SAVED AS 'TEN764653/A'

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE TOTAL **ENTRY** SESSION FULL ESTIMATED COST

178.80 179.22

FILE 'CAPLUS' ENTERED AT 17:22:01 ON 16 NOV 2006 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 16 Nov 2006 VOL 145 ISS 21 FILE LAST UPDATED: 15 Nov 2006 (20061115/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/infopolicy.html

=> s 13

L4 9 L3

=> d 14 1-9 bib abs fhitstr

- L4 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN
- AN 2006:579497 CAPLUS
- DN 145:62925
- TI Preparation of N-acylsulfonamide apoptosis promoters
- IN Bruncko, Milan; Ding, Hong; Elmore, Steven; Kunzer, Aaron; Lynch, Christopher L.; Mcclellan, William; Park, Cheol-Min; Petros, Andrew; Song, Xiaohong; Wang, Xilu; Tu, Noah; Wendt, Michael
- PA USA
- SO U.S. Pat. Appl. Publ., 142 pp., Cont.-in-part of Ser. No. US 2004-988338, filed on 12 Nov 2004 which CODEN: USXXCO
- DT Patent
- LA English

1711.	CIVI J				
	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2006128706	A1	20060615	US 2005-127940	20050512
	US 2005159427	A1	20050721	US 2004-988338	20041112
PRAI	US 2003-519695P	P	20031113		
	US 2004-988338	A2	20041112		
os	MARPAT 145:62925				
GI					

$$Z^{1}$$
 $N$ 
 $S$ 
 $D^{1}$ 
 $A^{1}$ 
 $B^{1}$ 
 $D^{1}$ 

Disclosed are N-acylsulfonamide compds. I [A1 = N, CA2; one or two or three or each of A2, B1, D1 and E1 = R1, OR1, SR1, NHR1, etc., and the remainder = H, halo, CN, etc.; Y1 = H, CN, NO2, CO2H, etc.; or B1 and Y1, together with the atoms to which they are attached, = imidazole or triazole; one or two or each of A2, D1 and E1 = R1, OR1, SR1, etc., and the remainder = H, halo, CF3, etc.; R1 = Ph (un) fused with (hetero) arene, heteroaryl (un) fused with (hetero) arene, etc.; Z1 = substituted Ph (un) fused with (hetero) arene, heteroaryl (un) fused with (hetero) arene] which inhibit the activity of anti-apoptotic protein family members, compns. containing the compds. I and uses of the compds. I for preparing medicaments for treating diseases during which occurs expression of one or more than one anti-apoptotic protein family member. Over 460 synthetic examples were presented (no characterization data for intermediates). E.g., a multi-step synthesis of (1R)-II, starting from piperazine and Et 4-fluorobenzoate, was given. The compds. I were found to be inhibitors of anti-apoptotic Bcl-XL protein and anti-apoptotic Bcl-2 (data given). ΙT 852809-46-2P

II

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of N-acylsulfonamide apoptosis promoters)

RN 852809-46-2 CAPLUS

CN Benzamide, N-[[3-nitro-4-[[2-(phenylthio)ethyl]amino]phenyl]sulfonyl]-4-[4-[(1-phenyl-1H-pyrazol-5-yl)methyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)

```
ANSWER 2 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN
Ъ4
     2005:472142 CAPLUS
AN
     143:26639
DN
ΤI
     Preparation of N-acylsulfonamide apoptosis promoters
     Bruncko, Milan; Ding, Hong; Elmore, Steven; Kunzer, Aaron R.; Lynch,
IN
     Christopher L.; Mcclellan, William; Park, Cheol-Min; Petros, Andrew; Song,
     Xiaohong; Wang, Xilu; Tu, Noah; Wendt, Michael D.
PA
     Abbott Laboratories, USA
SO
     PCT Int. Appl., 507 pp.
     CODEN: PIXXD2
DT
     Patent
LΑ
     English
FAN.CNT 3
     PATENT NO.
                         KIND
                                DATE
                                            APPLICATION NO.
                                                                    DATE
                                            -----
                                _____
PΙ
     WO 2005049594
                          A1
                                20050602
                                            WO 2004-US37911
                                                                   20041112
            AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA; NI,
             NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
             TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
             AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
             EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO,
             SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
             NE, SN, TD, TG
     AU 2004290666
                          A1
                                20050602
                                            AU 2004-290666
                                                                    20041112
```

20050602

20060802

20031113

20041112

IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS

CA 2004-2546101

EP 2004-810896

AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,

20041112

20041112

WO 2004-US37911 OS MARPAT 143:26639

CA 2546101

EP 1685119

PRAI US 2003-519695P

AA

**A**1

Ρ

W

GΙ

$$\begin{array}{c|c}
 & O \\
 & O \\$$

AB Disclosed are N-acylsulfonamide compds. I [A1 = N, CA2; one or two or three or each of A2, B1, D1 and E1 = R1, OR1, SR1, NHR1, etc., and the remainder = H, halo, CN, etc.; Y1 = H, CN, NO2, CO2H, etc.; or B1 and Y1, together with the atoms to which they are attached, = imidazole or triazole; one or two or each of A2, D1 and E1 = R1, OR1, SR1, etc., and the remainder = H, halo, CF3, etc.; R1 = Ph (un) fused with (hetero) arene, heteroaryl (un)fused with (hetero)arene, etc.; Z1 = substituted Ph (un) fused with (hetero) arene, heteroaryl (un) fused with (hetero) arene] which inhibit the activity of anti-apoptotic protein family members, compns. containing the compds. I and uses of the compds. I for preparing medicaments for treating diseases during which occurs expression of one or more than one anti-apoptotic protein family member. Over 450 synthetic examples were presented (no characterization data for intermediates). E.g., a multi-step synthesis of (1R)-II, starting from piperazine and Et 4-fluorobenzoate, was given. The compds. I were found to be inhibitors of anti-apoptotic Bcl-XL protein and anti-apoptotic Bcl-2 (data given). IT 852809-46-2P

II

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of N-acylsulfonamide apoptosis promoters)

RN 852809-46-2 CAPLUS

CN Benzamide, N-[[3-nitro-4-[[2-(phenylthio)ethyl]amino]phenyl]sulfonyl]-4-[4-[(1-phenyl-1H-pyrazol-5-yl)methyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} & & & & & & \\ & & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & \\ & & & \\ & &$$

RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
L4
     ANSWER 3 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN
     2005:472141 CAPLUS
AN
     143:26638
DN
ΤI
     Preparation of N-acylsulfonamide apoptosis promoters
IN
     Bruncko, Milan; Elmore, Steven; Kunzer, Aaron R.; Lynch, Christopher L.;
     Wang, Xilu; Wendt, Michael D.
     Abbott Laboratories, USA
PA
SO
     PCT Int. Appl., 471 pp.
     CODEN: PIXXD2
DT
     Patent
LΑ
     English
FAN.CNT 3
     PATENT NO.
                         KIND
                                            APPLICATION NO.
                                DATE
                                                                    DATE
```

						1111		D1 11 L				10111	1011			D	7111	
							-											
PΙ	WO	2005	04959	93		A2		2005	0602	1	WO 2	004-1	US36	770		2	00413	103
	WO	2005	0495	93		A3		2005	0707									
		W:	ΑE,	AG,	AL,	AM,	AT,	AU,	ΑZ,	BA,	BB,	BG,	BR,	BW,	BY,	ΒZ,	CA,	CH,
			CN,	co,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	EG,	ES,	FI,	GB,	GD,
			GE,	GH,	GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	KE,	KG,	ΚP,	KR,	KZ,	LC,
			LK,	LR,	LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MZ,	NA,	NI,
			NO,	ΝZ,	OM,	PG,	PH,	PL,	PT,	RO,	RU,	SC,	SD,	SE,	SG,	SK,	SL,	SY,
			ТJ,	TM,	TN,	TR,	TT,	ΤZ,	UA,	UG,	US,	UZ,	VC,	VN,	YU,	ZA,	ZM,	ZW
		RW:	BW,	GH,	GM,	ΚE,	LS,	MW,	ΜZ,	NA,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	AM,
			ΑZ,	BY,	KG,	ΚZ,	MD,	RU,	ТJ,	TM,	ΑT,	BE,	BG,	CH,	CY,	CZ,	DE,	DK,
			EE,	ES,	FI,	FR,	GB,	GR,	HU,	ΙE,	IS,	IT,	LU,	MC,	NL,	PL,	PT,	RO,
			SE,	SI,	SK,	TR,	BF,	ВJ,	CF,	CG,	CI,	CM,	GA,	GN,	GQ,	GW,	ML,	MR,
			NE.	SN.	TD.	TG												

PRAI US 2003-519695P P 20031113

OS MARPAT 143:26638

GI

AΒ Disclosed are N-acylsulfonamide compds. I [A1 = N, CA2; one or two or three or each of A2, B1, D1 and E1 = R1, OR1, SR1, NHR1, etc., and the remainder = H, halo, CN, etc.; Y1 = H, CN, NO2, CO2H, etc.; or B1 and Y1, together with the atoms to which they are attached, = imidazole or triazole; one or two or each of A2, D1 and E1 = R1, OR1, SR1, etc., and the remainder = H, halo, CF3, etc.; R1 = Ph (un) fused with (hetero) arene, heteroaryl (un)fused with (hetero)arene, etc.; Z1 = substituted Ph (un) fused with (hetero) arene, heteroaryl (un) fused with (hetero) arene] which inhibit the activity of anti-apoptotic protein family members, compns. containing the compds. I and uses of the compds. I for preparing medicaments for treating diseases during which occurs expression of one or more than one anti-apoptotic protein family member. Over 440 synthetic examples were presented (no characterization data for intermediates). E.g., a multi-step synthesis of (1R)-II, starting from piperazine and Et 4-fluorobenzoate, was given. The compds. I were found to be inhibitors of anti-apoptotic Bcl-XL protein and anti-apoptotic Bcl-2 (data given). IT 852809-46-2P

II

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of N-acylsulfonamide apoptosis promoters)

RN 852809-46-2 CAPLUS

CN Benzamide, N-[[3-nitro-4-[[2-(phenylthio)ethyl]amino]phenyl]sulfonyl]-4-[4-[(1-phenyl-1H-pyrazol-5-yl)methyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)

L4ANSWER 4 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:756697 CAPLUS

DN 141:260772

Preparation of N-arylheteroaryls, in particular N-phenylpiperazinyl TI methanones, as inhibitors of tubulin polymerization and their compositions for treatment of cancer

Le-Brun, Alain; Thompson, Fabienne; Tiraboschi, Gilles; Mailliet, Patrick; IN Salvino, Joseph M.

PA Aventis Pharma S.A., Fr.

SO PCT Int. Appl., 197 pp.

CODEN: PIXXD2

DTPatent

LΑ French

FAN.	CNT	2																
		PENT :									APPL					D	ATE	
PI	WO	2004	0787	32		A1		2004	0916							2	0040	126
	WO	2004																
		W:	ΑE,	AG,	AL,	AM,	AT,	ΑU,	ΑZ,	BA,	BB,	BG,	BR,	BW,	BY,	BZ,	CA,	CH,
			CN,	co,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	EG,	ES,	FI,	GB,	GD,
			GE,	GH,	GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	ΚE,	KG,	ΚP,	KR,	ΚZ,	LC,
								LV,										
		RW:						MW,										
								DK,										
								SI,			BF,	ВJ,	CF,	CG,	CI,	CM,	GA,	GN,
								SN,										
		2850																
		2004																
	CA	2512	243			AA		2004	0916	(	CA 2	004-	2512	243		20	0040	126
	EΡ	1590																
		R:						ES,										PT,
			IE,	SI,	LT,	LV,	FI,	RO,	MK,	CY,	AL,	TR,	BG,	CZ,	EE,	HU,	SK	
	BR	2004	0070	88		Α		2006	0124		BR 2	004-	7088			20	0040	126
•		2006									JP 2	006-	5056	60		20	0040	126
PRAI		2003																
		2003																
	WO	2004	-FR1	68		W		2004	0126									
os	MAI	RPAT	141:	2607	72													•
GI																		

AB Title compds. I [wherein R1, R2 = independently (un)substituted hetero/aryl; L = CH2 and derivs., C(:O), C(:S), C:NOH and derivs.; R2 = (C5-C7)cycloalkyl; R3 = independently H, OH and derivs., S(O)nH and derivs., NH2 and derivs., halo, cycloalkylene, (un)substituted hetero/aryl, cycloalkyl, alkyl, etc.; R4 = H, alk(en/yn)yl, cyclopropyl, alkoxy, S-alkyl, F, Cl, Br; n = 0-2; X = N, CH; G = substituted piperazine, piperidine, 1,2,5,6-tetrahydropyridine; their racemics, stereoisomers, tautomers, prodrugs, and pharmaceutically acceptable salts] were prepared as inhibitors of tubulin polymerization and of tumor and endothelial

II

cell proliferation in vitro, and for use in treatment of cancer. A combinatorial library of N-phenylpiperazinyl pyrazolyl ketones is given. For example, II was prepared from 5-methyl-2-phenyl-2H-pyrazole-3-carboxylic acid and 1-(3-chlorophenyl)piperazine. II gave an IC50 of 0.2  $\mu\rm M$  for inhibition of tubulin polymerization, an IC50 value of 0.002  $\mu\rm M$  for inhibition of HCT116 cells proliferation, and a 22% detachment of the endothelial HDMEC cells at a concentration of 1  $\mu\rm M$ . Thus, I and their pharmaceutical compns. are useful for treating cancer (no data).

IT 729605-21-4P, [4-(3-Chlorophenyl)piperazin-1-yl](5-methyl-2-phenyl-2H-pyrazol-3-yl)methanone

RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(inhibitor of tubulin polymerization; preparation of N-arylheteroaryls, in particular N-phenylpiperazinyl methanones, as inhibitors of tubulin polymerization and their compns. for treatment of cancer)

RN 729605-21-4 CAPLUS

CN Piperazine, 1-(3-chlorophenyl)-4-[(3-methyl-1-phenyl-1H-pyrazol-5-yl)carbonyl]- (9CI) (CA INDEX NAME)

# RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:611924 CAPLUS

DN 141:157136

TI Preparation of N-arylheteroaryls, in particular N-phenylpiperazinyl methanones, as inhibitors of tubulin polymerization and their compositions for treatment of cancer

IN Le Brun, Alain; Thompson, Fabienne; Tiraboschi, Gilles; Salvino, Joseph; Mailliet, Patrick

PA Aventis Pharma SA, Fr.

SO Fr. Demande, 80 pp.

CODEN: FRXXBL

DT Patent

LA French

FAN.	CNT 2 PATENT					DATE			ICAT				D2	ATE	
ΡI	FR 285					2004	0730						21	0030	128
	AU 2004												_		
	CA 2512		00												
	WO 200														
	WO 2004							WO Z	004-	EKTO.	0		۷.	0040	120
		AE,						BB.	BG.	BR.	BW.	BY.	BZ.	CA.	CH.
			co,												
			GH,										-		-
			LR,												
	RW	: BW,													
			CH,		-	-				-	-	-			
			NL,												
		-	GW,		-	-	-	,	,	,	,	,	,	,	,
	US 200							US 2	004-	7646	53		2	0040	126
	EP 159														
		ΑT,													
			SI,												,
	BR 200														126
	JP 200														
PRAI	FR 200														
	US 200	3-455	120P	P		2003	0317								
	FR 200														
	WO 200														
os	MARPAT						•								
GI			_												

AB Title compds. I [wherein R1, R2 = independently (un) substituted hetero/aryl; L = CH2 and derivs., C(:O), C(:S), C:NOH and derivs.; R3, R4 = independently H, alkyl, cycloalkylene, OH and derivs., S(O)nH and derivs., NH2 and derivs., halo, (un) substituted hetero/aryl, cycloalkyl; n = 0-2; X = N, CH; G = substituted piperazine, piperidine,1,2,5,6-tetrahydropyridine; their racemics, stereoisomers, tautomers, prodrugs, and pharmaceutically acceptable salts] were prepared as inhibitors of tubulin polymerization and of tumor and endothelial cell proliferation in vitro, and for use in treatment of cancer. A combinatorial library of N-phenylpiperazinyl pyrazolyl ketones is given. For example, II was prepared from 5-methyl-2-phenyl-2H-pyrazole-3-carboxylic acid and 1-(3-chlorophenyl)piperazine. II gave an IC50 of 0.2  $\mu$ M for inhibition of tubulin polymerization, an IC50 value of 0.002 µM for inhibition of HCT116 cells proliferation, and a 22% detachment of the endothelial HDMEC cells at a concentration of 1  $\mu M$ . Thus, I and their pharmaceutical compns. are useful for treating cancer (no data).

II

useful for treating cancer (no data).

729605-21-4P, [4-(3-Chlorophenyl)piperazin-1-yl](5-methyl-2-phenyl-2H-pyrazol-3-yl)methanone
RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study);
CMBI (Combinatorial study); PREP (Preparation); USES (Uses)
 (inhibitor of tubulin polymerization; preparation of N-arylheteroaryls, in particular N-phenylpiperazinyl methanones, as inhibitors of tubulin polymerization and their compns. for treatment of cancer)

729605-21-4 CAPLUS

Piperazine, 1-(3-chlorophenyl)-4-[(3-methyl-1-phenyl-1H-pyrazol-5-yl)carbonyl]- (9CI) (CA INDEX NAME)

RN

CN

## RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:20666 CAPLUS

DN 140:77166

TI Preparation of arylcarbonylpiperazines and heteroarylcarbonylpiperazines for treating benign and malignant tumor diseases

IN Emig, Peter; Gerlach, Matthias; Polymeropoulos, Emmanuel; Mueller, Gilbert; Schmidt, Peter; Baasner, Silke; Guenther, Eckhard

PA Zentaris Gmbh, Germany

SO PCT Int. Appl., 45 pp.

CODEN: PIXXD2

DT Patent

LA German

	PATENT NO.  WO 2004002965						APPLICATION NO.					DATE 					
PI	WO 2004	10029	<b>6</b> 5		A1	-	2004	0108		 WO 2	003-	EP65	 55		2	0030	620
	W:	ΑU,	BR,	BY,	CA,	CN,	CO,	GE,	HR,	ΗU,	ID,	IL,	IN,	IS,	JP,	KR,	ΚZ,
		LT,	LV,	MK,	ΜX,	NO,	NZ,	PH,	PL,	RO,	RU,	SG,	UA,	UZ,	YU,	zA	
	RW:	AM,	ΑZ,	BY,	KG,	KZ,	MD,	RU,	ТJ,	TM,	AT,	BE,	BG,	CH,	CY,	CZ,	DE,
		DK,	EE,	ES,	FI,	FR,	GB,	GR,	HU,	IE,	IT,	LU,	MC,	NL,	PT,	RO,	SE,
		SI,	SK,	TR				•									
	AU 2003	32465	71		A1		2004	0119		AU 2	003-2	2465	71		2	0030	620
	EP 1517	7898			<b>A</b> 1		2005	0330		EP 2	003-	7614	82		2	0030	620
	R:	ΑT,	BE,	CH,	DE,	DK,	ES,	FR,	GB,	GR,	IT,	LI,	LU,	NL,	SE,	MC,	PT,
		IE,	SI,	LT,	LV,	FI,	RO,	MK,	CY,	ΑL,	TR,	BG,	CZ,	EE,	HU,	SK	
	BR 2003	30122	94		Α		2005	0412		BR 2	003-	1229	4		2	0030	620
	CN 1665	792			Α		2005	0907		CN 2	003-	8154	85		2	0030	620
	NZ 5379	916			Α		2005	1125		NZ 2	003-	5379	16		2	0030	620
	JP 2005	55389	68		Т2		2005	1222		JP 2	004-	5166	32		2	0030	620
	CA 2433	3983			AA		2003	1229		CA 2	003-2	2433	983		2	0030	627
•	US 2004	10977	34		A1		2004	0520		US 2	003-	6085	20		2	0030	627
	ZA 2004	10096	10		Α		2005	0418		ZA 2	004-	9610			2	0041	126
	NO 2005	50004	28		Α		2005	0125		NO 2	005-	428			21	0050	125
PRAI	US 2002	2-393	027P		P		2002	0629									
	WO 2003	3-EP6	555		W		2003	0620									
os	MARPAT	140:	7716	6													
GI																	

Title compds. [I; R1 = (substituted) fluoren-9-one, isoxazolyl, cinnolinyl, isothiazolyl, isoquinolinyl, 9H-fluorenyl, 9H-xanthenyl, 1H-pyrazolyl; R2 = O, S; R3 = H, (substituted) alkyl, halo, CO2H, CONH2; R4 = (substituted) (hetero)aryl, alkylaryl, alkylhetaryl; m, n = 0-3], were prepared Thus, 9-fluorenone-4-carbonyl chloride in DMF was successively treated with N-methylmorpholine, 1-(3,5-dimethoxyphenyl)piperazine, and 1-benzotriazolyltripyrrolidinophosphonium hexafluorophosphate followed by stirring for 12 h at room temperature to give 79,3% 4-[4-(3,5-dimethoxyphenyl)piperazine-1-carbonyl]fluoren-9-one. The latter inhibited proliferation in XTT cytotoxicity test in human tumor cells with EC50 = 0,2-0,555 μg/mL.

IT 640286-88-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of arylcarbonylpiperazines and heteroarylcarbonylpiperazines for treating benign and malignant tumor diseases)

RN 640286-88-0 CAPLUS

CN Piperazine, 1-(3-methoxyphenyl)-4-[(1-phenyl-1H-pyrazol-5-yl)carbonyl]-(9CI) (CA INDEX NAME)

### RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1988:221717 CAPLUS

DN 108:221717

TI Preparation and testing of new aryl-substituted (N-piperidinyl)methyl- and (N-piperazinyl)methylazoles having antipsychotic properties

IN Van Wijngaarden, Ineke; Kruse, Cornelis G.; Van der Heyden, Johannes; Tulp, Martinus T. M.

PA Duphar International Research B. V., Neth.

SO Eur. Pat. Appl., 20 pp. CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

PATENT NO. KIND DATE APPLICATION NO. DATE

ΡI	EP 241053	A1	19871014	EP 1987-200296	19870224
	EP 241053	В1	19921111		
	R: AT, BE, CH,	DE,	ES, FR, GB,	GR, IT, LI, LU, NL, SE	
	NL 8600488	Α	19870916	NL 1986-488	19860227
	DK 8700930	A	19870828	DK 1987-930	19870224
	ZA 8701335	Α	19870930	ZA 1987-1335	19870224
	US 4772604	Α	19880920	US 1987-18164	19870224
	IL 81669	A1	19901129	IL 1987-81669	19870224
	CA 1279645	A1	19910129	CA 1987-530424	19870224
	AT 82281	E	19921115	AT 1987-200296	19870224
	ES 2052545	Т3	19940716	ES 1987-200296	19870224
	AU 8769247	A1	19870903	AU 1987-69247	19870225
	AU 585131	B2	19890608		
	JP 62205058	A2	19870909	JP 1987-40530	19870225
	JP 07098800	B4	19951025		
	US 4874770	Α	19891017	.US 1988-214310	19880701
PRAI	NL 1986-488	Α	19860227		
	EP 1987-200296	Α	19870224		
	US 1987-18164	A3	19870224		
os	MARPAT 108:221717				
GI					

AB The title compds. [I; R = alkyl, hydroxyalkyl, alkoxy, alkylthio, OH, amine, acyl, alkoxycarbonyl, NO2, CN, halo, CF3, etc.; R1,R2,R3 = H, alkyl; R4 = (substituted)aryl, heteroaryl, acyl; R5 = H, OH, bond to adjacent carbon; A = 5-membered N-containing heterocyclyl; X = N, CR5; n = 0-4] and salts and prodrugs thereof were prepared as antipsychotics. N-4-(Fluorophenyl)piperazine was stirred with 37% aqueous HCHO in EtOH for 30 min. 2-Phenylpyrrole was added and the mixture was refluxed 4 h to give phenylpiperazinylmethyl pyrrole II. Preferred II bound to dopamine D2 receptors with Ki's of <10 nm.

IT 114518-36-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of, as antipsychotic)

RN 114518-36-4 CAPLUS

CN Piperazine, 1-[[1-(3-chlorophenyl)-1H-pyrazol-5-yl]methyl]-4-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)

$$N$$
 $CH_2$ 
 $N$ 
 $N$ 
 $MeO$ 



L4 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1974:449701 CAPLUS

DN 81:49701

TI Pyrazole derivatives

IN Hadamik, Harri; Schulte, Karl; Koppe, Volker; Poetsch, Eike

PA Merck Patent G.m.b.H.

SO Ger. Offen., 30 pp. CODEN: GWXXBX

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2258033	A1	19740530	DE 1972-2258033	19721127
	JP 49082669	A2	19740808	JP 1973-129311	19731119
	ES 420898	<b>A</b> 1	19760401	ES 1973-420898	19731127
PRAT	DE 1972-2258033	A	19721127		

GI For diagram(s), see printed CA Issue.

AB Central depressant piperazinyl-alkylpyrazoles I [R = H, Me, Ph, Ac, Bz, COPr, COCH:CHPh COC6H4NH2-p, COC6H2(OMe)3-3,4,5, CONH2, CONMe2, CO2Et; R1 = Me, H; R2 = substituted phenyl; n = 1-4] and some related piperidinoalkylpyrazoles (67 compds.) were prepared by dehydrogenating II. Thus, I (R = H, R1 = Me, R2 = C6H4Cl-3 n = 2) was obtained by halogenating-dehydrohalogenating II with SO2Cl2. II (R = H, R1 = Me, R2 = C6H4Cl-3, n = 2) was prepared by treating ClCH2CH2COCH:CHMe with N-(m-chloro-phenyl)piperazine and N2H4.

IT 49654-35-5P

RN 49654-35-5 CAPLUS

CN Piperazine, 1-(3-chlorophenyl)-4-[2-(3-methyl-1-phenyl-1H-pyrazol-5-yl)ethyl]-, diperchlorate (9CI) (CA INDEX NAME)

CM 1

CRN 49869-03-6 CMF C22 H25 C1 N4

2 CM

CRN 7601-90-3 CMF Cl H O4

```
L4
    ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN
    1973:492277 CAPLUS
AN
```

79:92277 DN

Arylpiperazines ΤI

IN Poetsch, Eike

PA Merck Patent G.m.b.H.

SO Ger. Offen., 38 pp.

CODEN: GWXXBX

DTPatent

LA German

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
ΡI	DE 2201889	A1	19730719	DE 1972-2201889	19720115
	NL 7215334	Α	19730717	NL 1972-15334	19721113
	SE 397530	В	19771107	SE 1972-15765	19721204
	ZA 7208625	Α	19730829	ZA 1972-8625	19721205
	AU 7249852	A1	19740613	AU 1972-49852	19721208
	PL 83741	P	19760131	PL 1972-159971	19721229
	GB 1360959	A	19740724	GB 1973-435	19730103

DK	134177	В	19760927	DK	1973-67	19730105
US	3926999	Α	19751216	US	1973-322184	19730109
BE	793955	A1	19730712	BE	1973-126376	19730112
DD	104080	С	19740220	DD	1973-168218	19730112
HU	165959	P	19741228	HU	1973-ME1592	19730112
AT	7300262	Α	19750715	AT	1973-262	19730112
AT	329062	В	19760426			
JP	50004085	A2	19750116	JΡ	1973-6335	19730113
FR	2168357	<b>A</b> 1	19730831	FR	1973-1270	19730115
CH	587270	Α	19770429	CH	1973-526	19730115
PRAI DE	1972-2201889	Α	19720115			

GI For diagram(s), see printed CA Issue.

Pyrazolylalkylpiperazines I (R = H, Me, Ph, Ac, Bz, PrCO, PhCH:CHCO, p-H2NC6H4CO, 3,4,5-(MeO)3C6H2CO, Me2NCO, EtO2C; R1 = H, 2-Cl, 3-Cl, 4-Cl, 3-Me, 4-Me, 3-CF3, 3-CMe3, 4-OMe; n = 1-4) were prepared by cyclizing the appropriate arylpiperazinylalkadienes with N2H4. Thus, MeCCl:CH2 was treated with ClCH2CH2COCl, followed by Et3N to give ClCH:CHCOCH:CH2, which was treated with 1-m-chlorophenylpiperazine to give 1-(4-m-chlorophenylpiperazino)-5-chloro-4-hexen-3-one, and cyclized with N2H4 to I (R = H, R1 = 4-Cl, n = 2).

IT 49654-35-5P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)

RN 49654-35-5 CAPLUS

CN Piperazine, 1-(3-chlorophenyl)-4-[2-(3-methyl-1-phenyl-1H-pyrazol-5-yl)ethyl]-, diperchlorate (9CI) (CA INDEX NAME)

CM 1

CRN 49869-03-6 CMF C22 H25 C1 N4

CM 2

7601-90-3 CRN CMF Cl H O4

```
=> d 14 6-9 bib hitstr
```

L4ANSWER 6 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:20666 CAPLUS

140:77166 DN

TI Preparation of arylcarbonylpiperazines and heteroarylcarbonylpiperazines for treating benign and malignant tumor diseases

IN Emig, Peter; Gerlach, Matthias; Polymeropoulos, Emmanuel; Mueller, Gilbert; Schmidt, Peter; Baasner, Silke; Guenther, Eckhard

PA Zentaris Gmbh, Germany

SO PCT Int. Appl., 45 pp. CODEN: PIXXD2

DTPatent

LΑ German

**FAM CMT 1** 

		NO.			KIN	D	DATE			APP]	LICAT	ION 1	NO.		D	ATE	
WO	2004	0029	65		A1	_	2004	0108	1	WO 2	2003-	EP65	<b></b> . 55		2	0030	620
	W:																
			-	-	-	-	-	-	-	-		•			•		
	RW:		•	•	•	•	•	•	•			•	•	•	•	•	•
					FI,	FR,	GB,	GR,	HU,	IE,	, IT,	LU,	MC,	NL,	PT,	RO,	SĒ,
	0000		•		- 4										_		
EΡ																	
	R:																PT,
		ΙE,	SI,	LT,	LV,	FI,	RO,	MK,	CY,	AL	, TR,	BG,	CZ,	EE,	HU,	SK	
							2005	0412		BR 2	2003-	1229	4		2	0030	620
CN	1665	792			Α												
ΝZ	5379	16			Α	·	2005	1125		NZ 2	2003-	5379	16		2	0030	620
JP	2005	5389	68		Т2		2005	1222		JP 2	2004-	5166	32		2	0030	620
CA	2433	983			AA		2003	1229		CA 2	2003-	2433	983		2	0030	627
US	2004	0977	34		<b>A</b> 1		2004	0520		US 2	2003-	6085	20		2	0030	627
ZΑ	2004	0096	10		A		2005	0418		ZA 2	2004-	9610			2	0041	126
NO	2005	0004	28		Α		2005	0125		NO 2	2005-	428			. 20	0050	125
US	2002	-393	027P		P		2002	0629									
WO	2003	-EP6	555		W		2003	0620									
MAI	RPAT	140:	7716	6													
	AU EP BR CN NZ JP CA US ZA NO US WO	MO 2004 W: RW:  AU 2003 EP 1517 R:  BR 2003 CN 1665 NZ 5379 JP 2005 CA 2433 US 2004 ZA 2004 NO 2005 US 2002 WO 2003	PATENT NO	PATENT NO.   WO 2004002965  W: AU, BR, LT, LV, RW: AM, AZ, DK, EE, SI, SK, AU 2003246571  EP 1517898 R: AT, BE, IE, SI, BR 2003012294 CN 1665792 NZ 537916 JP 2005538968 CA 2433983 US 2004097734 ZA 2004009610 NO 2005000428 US 2002-393027P WO 2003-EP6555	PATENT NO.	PATENT NO.  WO 2004002965  W: AU, BR, BY, CA, LT, LV, MK, MX, RW: AM, AZ, BY, KG, DK, EE, ES, FI, SI, SK, TR  AU 2003246571  EP 1517898  R: AT, BE, CH, DE, IE, SI, LT, LV, BR 2003012294  CN 1665792  NZ 537916  JP 2005538968  CA 2433983  US 2004097734  ZA 2004009610  NO 2005000428  US 2002-393027P  WO 2003-EP6555	PATENT NO.  WO 2004002965  W: AU, BR, BY, CA, CN, LT, LV, MK, MX, NO, RW: AM, AZ, BY, KG, KZ, DK, EE, ES, FI, FR, SI, SK, TR  AU 2003246571  EP 1517898  R: AT, BE, CH, DE, DK, IE, SI, LT, LV, FI, BR 2003012294  CN 1665792  NZ 537916  JP 2005538968  CA 2433983  US 2004097734  ZA 2004009610  NO 2005000428  US 2002-393027P  WO 2003-EP6555	PATENT NO.	PATENT NO.  WO 2004002965  W: AU, BR, BY, CA, CN, CO, GE, LT, LV, MK, MX, NO, NZ, PH, RW: AM, AZ, BY, KG, KZ, MD, RU, DK, EE, ES, FI, FR, GB, GR, SI, SK, TR  AU 2003246571  EP 1517898  R: AT, BE, CH, DE, DK, ES, FR, IE, SI, LT, LV, FI, RO, MK, BR 2003012294  CN 1665792  A 200503412  CN 1665792  A 20050907  NZ 537916  A 20050125  JP 2005538968  T2 2005125  CA 2433983  US 2004097734  A 20050125  US 2002-393027P  WO 2003-EP6555  W 20030620	PATENT NO.	PATENT NO.  WO 2004002965  A1 20040108  W: AU, BR, BY, CA, CN, CO, GE, HR, HU LT, LV, MK, MX, NO, NZ, PH, PL, RO RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM DK, EE, ES, FI, FR, GB, GR, HU, IE SI, SK, TR  AU 2003246571  A1 20040119  AU 2003246571  A1 20040119  AU 20050330  EP 3  R: AT, BE, CH, DE, DK, ES, FR, GB, GR IE, SI, LT, LV, FI, RO, MK, CY, AL BR 2003012294  A 20050412  BR 20050538968  T2 20051252  JP 2005538968  T2 2005125  JP 2005538968  T2 2005125  JP 2005538968  T2 2005125  JP 2005000428  A 20050125  NO 2005000428  A 20050125  NO 2005000428  US 2002-393027P  WO 2003-EP6555  W 20030620	PATENT NO.	PATENT NO.	PATENT NO.  WO 2004002965  W: AU, BR, BY, CA, CN, CO, GE, HR, HU, ID, IL, IN, LT, LV, MK, MX, NO, NZ, PH, PL, RO, RU, SG, UA, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, SI, SK, TR  AU 2003246571  EP 1517898  R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, LE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, BR 2003012294  CN 1665792  A 200503412  BR 2003012294  A 20050412  BR 2003-12294  CN 1665792  A 20050907  CN 2003-815485  NZ 537916  A 20051125  NZ 2003-537916  JP 2005538968  T2 20051222  JP 2004-516632  CA 2433983  AA 20031229  CA 2004097734  A1 20040520  JR 2003-608520  ZA 200409610  A 200500428  A 20050125  NO 2005-428  US 2002-393027P  P 20020629  WO 2003-EP6555  W 20030620	PATENT NO.  WE AU, BR, BY, CA, CN, CO, GE, HR, HU, ID, IL, IN, IS, LT, LV, MK, MX, NO, NZ, PH, PL, RO, RU, SG, UA, UZ, RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, SI, SK, TR  AU 2003246571  EP 1517898  R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, BR 2003012294  CN 1665792  A 20050412  BR 2003012294  A 20050412  BR 2003-12294  CN 1665792  A 20050907  CN 2003-815485  NZ 537916  A 2005125  NZ 2003-537916  JP 2005538968  T2 20051222  JP 2004-516632  CA 2433983  AA 20031229  CA 2004097734  A1 20040520  JS 2004-9610  NO 2005000428  A 20050125  NO 2005-428  US 2002-393027P  P 20020629  WO 2003-EP6555  W 20030620	PATENT NO. KIND DATE APPLICATION NO. DATE  WO 2004002965 A1 20040108 WO 2003-EP6555 20  W: AU, BR, BY, CA, CN, CO, GE, HR, HU, ID, IL, IN, IS, JP,     LT, LV, MK, MX, NO, NZ, PH, PL, RO, RU, SG, UA, UZ, YU,     RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY,     DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT,     SI, SK, TR  AU 2003246571 A1 20040119 AU 2003-246571 20  R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE,     IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU,     IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU,     S37916 A 20050125 NZ 2003-537916 20  CA 2433983 AA 20031229 CA 2003-2433983 20  CA 2433983 AA 20031229 CA 2003-2433983 20  CA 2004009610 A 20050418 ZA 2004-9610 20  NO 2005000428 A 20050125 NO 2005-428 20  US 2002-393027P P 20020629  WO 2003-EP6555 W 20030620	PATENT NO.

IT 640286-88-0P 640287-01-0P

> RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

(preparation of arylcarbonylpiperazines and heteroarylcarbonylpiperazines for treating benign and malignant tumor diseases)

RN 640286-88-0 CAPLUS 
$$\begin{array}{c|c} Ph & O & \\ \hline & O & \\ N & C & N \end{array}$$

RN 640287-01-0 CAPLUS

CN Piperazine, 1-(3-hydroxyphenyl)-4-[(1-phenyl-1H-pyrazol-5-yl)carbonyl]-(9CI) (CA INDEX NAME)

### RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1988:221717 CAPLUS

DN 108:221717

TI Preparation and testing of new aryl-substituted (N-piperidinyl)methyl- and (N-piperazinyl)methylazoles having antipsychotic properties

IN Van Wijngaarden, Ineke; Kruse, Cornelis G.; Van der Heyden, Johannes; Tulp, Martinus T. M.

PA Duphar International Research B. V., Neth.

SO Eur. Pat. Appl., 20 pp.

CODEN: EPXXDW

DT Patent

LA English

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 241053	A1	19871014	EP 1987-200296	19870224
	EP 241053 R: AT, BE, C	B1	19921111	GR, IT, LI, LU, NL, SE	
	NL 8600488	A A	19870916	NL 1986-488	19860227
	DK 8700930	Α	19870828	DK 1987-930	19870224
	ZA 8701335	Α	19870930	ZA 1987-1335	19870224
	US 4772604	Α.	19880920	US 1987-18164	19870224
	IL 81669	A1	19901129	IL 1987-81669	19870224
	CA 1279645	A1	19910129	CA 1987-530424	19870224
	AT 82281	E	19921115	AT 1987-200296	19870224
	ES 2052545	Т3	19940716	ES 1987-200296	19870224
	AU 8769247	A1	19870903	AU 1987-69247	19870225
	AU 585131	. B2	19890608		
	JP 62205058	A2	19870909	JP 1987-40530	19870225
	JP 07098800	B4:	19951025		

	US 4874770	Α	19891017	US	1988-214310	19880701
PRAI	NL 1986-488	Α	19860227			
	EP 1987-200296	Α	19870224			
	US 1987-18164	A3	19870224			
OS	MARPAT 108:221717					
IT	114518-36-4P 114518-	38-6P				
	RL: BAC (Biological	activi	ty or effect	or,	except adverse);	BSU (Biological
	study, unclassified)	; SPN	(Synthetic p	repa	aration); THU (Th	erapeutic use);
	BIOL (Biological stu-	dy); Pl	REP (Prepara	tio	n); USES (Uses)	
	(preparation of,	as ant:	ipsychotic)			
RN	114518-36-4 CAPLUS					
CN	Piperazine, $1-[[1-(3$	-chlore	ophenyl)-1H-	pyra	azol-5-yl]methyl]	-4-(2-
	methoxyphenyl) - (9CI	) (CA	INDEX NAME)		_ · · · _	

114518-38-6 CAPLUS RN Phenol, 4-[5-[[4-(2-methoxyphenyl)-1-piperazinyl]methyl]-1H-pyrazol-1-yl]-CN (9CI) (CA INDEX NAME)

ANSWER 8 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN AN 1974:449701 CAPLUS 81:49701 DN ΤI Pyrazole derivatives IN Hadamik, Harri; Schulte, Karl; Koppe, Volker; Poetsch, Eike Merck Patent G.m.b.H. PΑ Ger. Offen., 30 pp. SO CODEN: GWXXBX DTPatent

L4

LA German FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PΤ	DE 2258033	 A1	19740530	DE 1972-2258033	19721127
PI	JP 49082669	A1 A2	19740330	JP 1972-2238033	19721127
	ES 420898	A1	19760401	ES 1973-420898	19731127
PRAI	DE 1972-2258033	A	19721127		23.022
IT	49654-35-5P				

RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)

RN 49654-35-5 CAPLUS

CN Piperazine, 1-(3-chlorophenyl)-4-[2-(3-methyl-1-phenyl-1H-pyrazol-5-yl)ethyl]-, diperchlorate (9CI) (CA INDEX NAME)

CM 1

CRN 49869-03-6 CMF C22 H25 Cl N4

CM 2

CRN 7601-90-3 CMF Cl H O4

```
ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN
AN
    1973:492277 CAPLUS
DN
    79:92277
ΤI
    Arylpiperazines
IN
    Poetsch, Eike
PA
    Merck Patent G.m.b.H.
SO
    Ger. Offen., 38 pp.
    CODEN: GWXXBX
DT
    Patent
    German
FAN.CNT 1
    PATENT NO.
                       KIND
                              DATE
                                          APPLICATION NO.
                                                                DATE
                        ____
                                          -----
PΙ
    DE 2201889
                              19730719
                        A1
                                          DE 1972-2201889
                                                                 19720115
    NL 7215334
                       Α
                              19730717
                                          NL 1972-15334
                                                                19721113
    SE 397530
                                          SE 1972-15765
                       В
                              19771107
                                                                19721204
                       Α
    ZA 7208625
                              19730829
                                          ZA 1972-8625
                                                                19721205
                       A1
    AU 7249852
                              19740613
                                          AU 1972-49852
                                                                19721208
                       P
    PL 83741
                              19760131
                                          PL 1972-159971
                                                                19721229
    GB 1360959
                        Α
                              19740724
                                          GB 1973-435
                                                                19730103
    DK 134177
                       В
                                          DK 1973-67
                              19760927
                                                                19730105
    US 3926999
                       Α
                              19751216
                                          US 1973-322184
                                                                19730109
                       A1
    BE 793955
                              19730712
                                          BE 1973-126376
                                                                19730112
                       С
    DD 104080
                              19740220
                                          DD 1973-168218
                                                                19730112
                       P
    HU 165959
                              19741228
                                          HU 1973-ME1592
                                                                19730112
                                          AT 1973-262
    AT 7300262
                              19750715
                       Α
                                                                19730112
                       В
    AT 329062
                              19760426
                              19750116
    JP 50004085
                       A2
                                          JP 1973-6335
                                                                19730113
    FR 2168357
                       A1
                              19730831
                                          FR 1973-1270
                                                                19730115
    CH 587270
                        Α
                              19770429
                                          CH 1973-526
                                                                19730115
                       Α
PRAI DE 1972-2201889
                              19720115
    49654-35-5P
    RL: SPN (Synthetic preparation); PREP (Preparation)
       (preparation of)
RN
    49654-35-5 CAPLUS
CN
    Piperazine, 1-(3-chlorophenyl)-4-[2-(3-methyl-1-phenyl-1H-pyrazol-5-
    yl)ethyl]-, diperchlorate (9CI) (CA INDEX NAME)
    CM
        49869-03-6
    CRN
    CMF C22 H25 C1 N4
```

CM 2

CRN 7601-90-3 CMF Cl H O4

=> file caold COST IN U.S. DOLLARS TOTAL SINCE FILE ENTRY SESSION FULL ESTIMATED COST 66.01 245.23 DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE TOTAL ENTRY SESSION CA SUBSCRIBER PRICE -6.75-6.75

FILE 'CAOLD' ENTERED AT 17:30:05 ON 16 NOV 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966 FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent